Vilazodone
Vilazodone. SSRI + 5-HT1A partial agonist — dual mechanism intended to soften initial worsening of anxiety + sexual side effects vs traditional… Oral half-life 35 h.
SSRI + 5-HT1A partial agonist — dual mechanism intended to soften initial worsening of anxiety + sexual side effects vs traditional SSRIs. Take with food (doubles AUC).
PK: ONE WRONG FIELD, AND FIXING IT ALONE IS THE WHOLE REPAIR — WHICH IS RARE IN THIS BATCH. The stored volume is very nearly the correct APPARENT volume; the defect is an F dividing it a second time. Its own citation gives "total drug clearance (19.9 and 25.1 L/h vs. 26.4 and 26.9 L/h)", where the latter pair are the healthy matched controls and, coming from a single oral dose with no intravenous arm, are necessarily apparent — against which the stored record asserted 38.5 L/h. Pinning F to 1 lands at 27.9, within four to six percent. The 72% figure in this literature is the label RELATIVE bioavailability of tablet against oral solution, and vilazodone has no intravenous form; I could not quote it from any abstract, so the SHAPE is reported rather than the sourcing asserted. The half-life was a cross-arm value: the verbatim options are "35.7 and 34.8 h mild and moderate vs. 37.0 and 34.8 h matched controls", 35 is none of them, and the nearest is the MILD RENAL IMPAIRMENT arm; it becomes a verbatim healthy-control value. ka 0.14 predicted a peak at 16.3 hours against a real 4-5, AND IS BYTE-SHARED WITH mesalamine, a colonic delayed-release drug where a rate that slow is appropriate. Exposure is roughly halved fasted and the label mandates food; that is not representable here.
Pharmacokinetics
- Oral — t½ 34.8 h · F 100% · Vd 1400 L
Sources: PMID:23417352